News

06 Sep 2018

Joint EBE-EFPIA Position on CE Marking

A Topic Group of the joint Personalised Medicine Working Group has been developing a slide deck highlighting the position of the pharmaceutical industry on the need to consider a risk-based a...

Read more
02 Aug 2018

EBE View on the SPC Manufacturing Waiver

The European Biopharmaceutical Enterprises (EBE) has just released its latest position paper, raising concerns on how the SPC manufacturing waiver will affect innovative biopharmaceutical companies,...

Read more
10 Jul 2018

New EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems and makes recommendations for equitable access for patients in Europe

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personal...

Read more
02 Jul 2018

EBE announces its 2018-2020 Board of Directors

Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 J...

Read more
20 Jun 2018

Incentives, IP and Smaller Companies – the story of uniQure

Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands  and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe genetic...

Read more
07 Jun 2018

KPMG Report: Site Selection for Life Sciences Companies in Europe 2018

EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...

Read more
28 May 2018

EBE statement on the European Commission’s proposal to introduce an SPC manufacturing waiver, which puts patient care at risk

Brussels – After the European Commission released its proposal to introduce a Supplementary Protection Certificates (SPCs) manufacturing waiver today, the European Biopharmaceutical Enterprises (EBE...

Read more
02 May 2018

In memory of Eugenio Aringhieri, CEO Dompé, member of the EBE Board of Directors

It is with great sadness that we received the news of the sudden and untimely passing of our Board member Eugenio Aringhieri, CEO Dompé, on 1 May 2018. Eugenio Aringhieri has contributed to th...

Read more
23 Mar 2018

Statement in response to the EU Council ratifying the Brexit transition deal

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today respond...

Read more
13 Mar 2018

European Investment Bank report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”

EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of neces...

Read more
1 2 3 8